Dasatinib Krka 50 mg tabletti, kalvopäällysteinen Finnország - finn - Fimea (Suomen lääkevirasto)

dasatinib krka 50 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - dasatinib - tabletti, kalvopäällysteinen - 50 mg - dasatinibi

Dasatinib Krka 70 mg tabletti, kalvopäällysteinen Finnország - finn - Fimea (Suomen lääkevirasto)

dasatinib krka 70 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - dasatinib - tabletti, kalvopäällysteinen - 70 mg - dasatinibi

Dasatinib Krka 80 mg tabletti, kalvopäällysteinen Finnország - finn - Fimea (Suomen lääkevirasto)

dasatinib krka 80 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - dasatinib - tabletti, kalvopäällysteinen - 80 mg - dasatinibi

Dasatinib Krka 100 mg tabletti, kalvopäällysteinen Finnország - finn - Fimea (Suomen lääkevirasto)

dasatinib krka 100 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - dasatinib - tabletti, kalvopäällysteinen - 100 mg - dasatinibi

Dasatinib Krka 140 mg tabletti, kalvopäällysteinen Finnország - finn - Fimea (Suomen lääkevirasto)

dasatinib krka 140 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - dasatinib - tabletti, kalvopäällysteinen - 140 mg - dasatinibi

Temybric Ellipta Európai Unió - finn - EMA (European Medicines Agency)

temybric ellipta

glaxosmithkline trading services limited - flutikasonifuroaatti, umeklidiniumbromidi, vilantterolitrifenkaatti - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - temybric ellipta on tarkoitettu huolto hoito aikuisilla potilailla, joilla on keskivaikea tai vaikea krooninen obstruktiivinen keuhkosairaus (copd), jotka eivät ole asianmukaisesti käsitelty yhdistelmä inhaloitava kortikosteroidi ja pitkävaikutteinen β2-agonisti tai yhdistelmä pitkävaikutteinen β2-agonisti ja pitkävaikutteisia muskariinireseptorin antagonisti (vaikutuksia oire, valvontaan ja ehkäisyyn pahenemisvaiheiden ks. kohta 5.

Bimzelx Európai Unió - finn - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressantit - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Dasatinib Accord Európai Unió - finn - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma Európai Unió - finn - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Librax 5 mg / 2,5 mg tabletti, päällystetty Finnország - finn - Fimea (Suomen lääkevirasto)

librax 5 mg / 2,5 mg tabletti, päällystetty

viatris oy - clidinium bromide, chlordiazepoxide - tabletti, päällystetty - 5 mg / 2,5 mg - klidiini ja psyykenlääke